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Abstract
Mutations in mitochondrial DNA (mtDNA) may cause maternally-inherited cardiomyopathy and heart failure. In
homoplasmy all mtDNA copies contain the mutation. In heteroplasmy there is a mixture of normal and mutant copies
of mtDNA. The clinical phenotype of an affected individual depends on the type of genetic defect and the ratios of mutant
and normal mtDNA in affected tissues. We aimed at determining the sensitivity of next-generation sequencing compared to
Sanger sequencing for mutation detection in patients with mitochondrial cardiomyopathy. We studied 18 patients with
mitochondrial cardiomyopathy and two with suspected mitochondrial disease. We ‘‘shotgun’’ sequenced PCR-amplified
mtDNA and multiplexed using a single run on Roche’s 454 Genome Sequencer. By mapping to the reference sequence, we
obtained 1,3006average coverage per case and identified high-confidence variants. By comparing these to .400 mtDNA
substitution variants detected by Sanger, we found 98% concordance in variant detection. Simulation studies showed that
.95% of the homoplasmic variants were detected at a minimum sequence coverage of 206while heteroplasmic variants
required .2006 coverage. Several Sanger ‘‘misses’’ were detected by 454 sequencing. These included the novel
heteroplasmic 7501T.C in tRNA serine 1 in a patient with sudden cardiac death. These results support a potential role of
next-generation sequencing in the discovery of novel mtDNA variants with heteroplasmy below the level reliably detected
with Sanger sequencing. We hope that this will assist in the identification of mtDNA mutations and key genetic
determinants for cardiomyopathy and mitochondrial disease.
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Introduction
Mitochondrial DNA and inheritance
Human mitochondrial DNA (mtDNA) is a circular, 16,569 base
sequence that encodes for 13 proteins, 22 transfer RNAs (tRNAs)
and 2 ribosomal RNAs [1]. MtDNA is essential for mitochondrial
energy production through oxidative phosphorylation, and
hundreds to thousands of mtDNA molecules may be found per
cell depending upon the energy requirements of the tissue [2].
In contrast to nuclear genes (nDNA), mtDNA is inherited only
from the mother [3]; therefore, mtDNA mutations associated with
inherited mitochondrial diseases follow the maternal lineage with
no transmission from the father [4]. Along the maternal lineage,
different amounts of a pathogenic and normal mtDNAs may be
inherited due to a genetic bottle neck during oogenesis and/or by
purifying selection of severe mtDNA mutations [5–7]. Homo-
plasmy describes the state where only mutant or variant mtDNAs
exist; whereas, in heteroplasmy there is a mixture of normal and
mutant or variant mtDNAs. Depending on the inheritance
(maternally-derived or de novo), segregation and postnatal selection,
an affected individual may have different ratios of mutant and
normal mtDNA in different tissues that result in mitochondrial
disease.
Mitochondrial DNA analysis by capillary and next
generation sequencing
Traditionally, the most comprehensive method used to detect
variants is Sanger capillary sequencing of whole mtDNA [8,9].
However, limitations prevent the routine use of whole mtDNA
studies by Sanger sequencing including the amount of labor and
time to manually inspect data for heteroplasmic mutations. Thus,
large scale efforts have been lacking to critically evaluate the role
of mtDNA mutations in human disease and to investigate the
scope of normal mtDNA variation in populations.
Recently, advances in microfluidics, digital imaging systems and
bioinformatics have lead to new sequencing methods or Next
GenerationSequencing (NGS)thatmayovercometheselimitations.
NGS methods can generate vast amounts of sequencing data in less
time and overall costs compared to traditional methods [10]. So,
many people believe that NGS may replace the traditional methods
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problem is the lack of patient studies to evaluate NGS for mutation
detection in comparison to Sanger sequencing [11]. In addition,few
NGS studies have focused on mtDNA [12,13] and the detection of
heteroplasmy[14,15]withonly one studyonpatients with known or
suspected mitochondrial disease [16].
The goal of this study was to explore NGS as a method to detect
mtDNA mutations in patients. Our aims were: (1) to identify all
mtDNA variants and potential mutations; (2) to evaluate variant
detection performance by comparing Roche 454 pyrosequencing
and Sanger sequencing technologies; and (3) to estimate the amount
of sequence coverage needed to detect homoplasmic and hetero-
plasmic mtDNA mutations or variants. In this report, we provide
the results of mtDNA analysis for 20 patients with mitochondrial
cardiomyopathy or suspected mitochondrial disease.
Results
Study population
We studied the mtDNA for 20 cases: 18 with mitochondrial
cardiomyopathy and 2 with suspected mitochondrial disease. For
each case, general features and the numbers of mtDNA variants
detected by Sanger and 454 sequencing are listed in Table 1.
MtDNA variant calls based on bioinformatics analysis of
454 sequences
For Sanger sequencing, we made 330,979 (99.9%) of 331,380
possible base calls (20 mtDNAs 616,569 bases/mtDNA).
Compared to the reference, we identified 460 mtDNA variants
that consisted of 414 single nucleotide substitutions, 410 homo-
plasmic and 4 heteroplasmic variants (Table 1). For each case, we
found 10 to 41 variants for an average of 23 variants per mtDNA;
details for the Sanger mtDNA variants will be in a separate report
(unpublished data).
For 454 sequencing, the results are provided in Table 1 for total
coverage and read length; Table S1 for detailed results for all
variants; and Table S2 for the mapping statistics. Using a single
454 run, we obtained approximately 440 Mb of raw sequencing
data from 1.2 million sequence reads. On average, 97.1% of the
reads and 98.4% of the bases mapped to the reference sequence
for each case (Table S2) which corresponded to an average
coverage (redundant and non-redundant sequences) of 1,3006
Table 1. Summary of mtDNA mapping and sequencing results for 20 cases.
Case Cardiac 454 Mapping Ave.
b 454 Variants
c Sanger Variants
a,c
No.
a Feature Depth Length Total Subst Indel Repeat Total Subst Indel Repeat
1
d HCM, HF 463 355 39 34 3 2 37 33 0 4
3 HCM 1,148 377 23 14 9 0 15 14 0 1
5 SCD, HF 944 373 33 31 2 0 32 30 0 2
6 DCM 1,542 374 28 17 11 0 18 17 0 1
7 HCM 1,561 372 25 17 8 0 18 17 0 1
8 HCM 1,294 381 24 15 8 1 18 15 0 3
9 HCM 1,506 374 20 12 7 1 15 13 0 2
10 HCM 1,635 377 19 10 8 1 12 10 0 2
11 HCM 1,393 373 25 10 14 1 14 10 1 3
12 HCM 1,442 379 17 10 6 1 13 11 0 2
13 DCM 1,042 373 39 32 6 1 36 32 1 3
14 DCM 1,498 372 35 25 7 3 28 25 0 3
15 DCM 2,140 376 35 25 10 0 26 25 0 1
16 DCM 1,823 381 15 960 10 901
17 DCM 1,134 375 38 30 8 0 30 29 0 1
18 DCM 1,431 369 45 36 8 1 41 36 1 4
19 DCM 1,147 368 17 791 10 703
20 DCM 2,054 380 51 40 11 0 41 39 0 2
NonCM1 ECHO nl 57
e 363 30 29 1 0 31 29 0 2
NonCM2 ECHO nl 716 376 23 14 9 0 15 13 0 2
AVE: 1,299 373 29 21 8 1 23 21 0 2
TOTAL: – – 581 417 151 13 460 414 3 43
Abbreviations: HCM= hypertrophic cardiomyopathy; HF= heart failure; DCM= dilated cardiomyopathy; SCD= sudden cardiac death; ECHO nl= echocardiograms
normal.
aAdditional case information and Sanger data analysis for haplotype and potential mutations are described in a separate report (unpublished data); cases 2 and 4 were
not included in the present study.
b454 mapping statistics: depth= average number of mapped sequences (non-redundant and redundant sequences) at each base position; length= average base
length of mapped sequences.
cMitochondrial DNA variants compared to NCBI Reference (NC_012920); Variant types: subst= single nucleotide substitutions; indel= insertion or deletion; repeat=
polymorphic repeats at positions: 303–315, 522–523, 574, 16180–16193 and 16519 (www.mitomap.com).
dFrom previously reported HCM family with MYH7 mutation [17].
eDecreased reads for NonCM1 possibly due to a pre-sequencing technical error.
doi:10.1371/journal.pone.0012295.t001
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380 bases) (Table 1).
Similar to previous studies on 454 sequencing, we found
variability in the depth of coverage between multiplexed cases and
along the same mtDNA molecule (Figure 1) [11,12,18]. We
attributed the lowest coverage due to a technical error in sample
preparation for NonCM1. When this case was excluded, we still
found that the read depth varied between cases up to ten-fold
(Figure 1). For coverage along the same mtDNA, we observed a
significant increase in the average coverage per base within the
regions where the PCR fragments overlap (mean=1,947,
SD=991) compared to the average coverage in non-overlapping
regions (mean=1,072, SD=543), p,0.0001. Overall, these
findings suggest that uniform coverage might be achieved by
single or two fragment LR-PCR instead of three fragments
[12,19].
We mapped the reads using the Roche GS Mapper software and
identified ‘‘high confidence’’ differences (HCDiffs) between each
mtDNA contig and the reference (Table 1). For the 20 cases, all
331,380 possible base callsweremade.These included 581 HCDiffs
with 417 single nucleotide substitutions, 411 homoplasmic and 6
heteroplasmic variants (Table 2 and Table S1). For each case, we
found 15 to 51 HCDiffs for an average of 29 variants per mtDNA.
Comparison of 454 and Sanger results indicated high
concordance for substitutions
We first compared the numbers and types of variants
(substitutions, indels and repeats) detected by 454 and Sanger
Figure 1. Variability in 454 sequence coverage. Total read coverage (redundant and non-redundant) is plotted at each mtDNA position (1 to
16569) and graphed as a continuous thin gray trace for each case (different shades for each case). The mean coverage for all 20 cases is represented
by a thick dark black trace. The shape of the traces shows coverage variability both between cases and along the same mtDNA. The black horizontal
lines (A, B & C) above the graph represent the three mtDNA PCR fragments used for 454 sequencing. Greater coverage was noted in the regions in
which the PCR fragments overlap compared to coverage in non-overlapping regions.
doi:10.1371/journal.pone.0012295.g001
Table 2. Discordant and/or heteroplasmic substitution mtDNA variants.
Method
a 454 depth Reason for
Type Sanger 454 Case No. Position (% variant)
b Type of error discordance
Homoplasmic + 2 9 8473T.C 231 (83%) 454 false - Homopolymer
+ 2 12 16566G.A 352(100%) 454 false - Software miscall
2 + 17 3010G.A 350 (100%) Sanger false - Miscall
2 + 20 15326A.G 405 (100%) Sanger false - Miscall
2 + 1 13967C.T 244 (100%) Sanger false - Poor data
Heteroplasmic 2 + NonCM2 16093T.C 246 (14%) Sanger false - Miscall
2 + 5 7501T.C 298 (18%) Sanger false - Miscall
++ 6 3243A.G 340 (19%) N/A N/A
++ 20 9854T.G 344 (39%) N/A N/A
++ 7 3645T.C 382 (47%) N/A N/A
++ NonCM1 15222A.G 45 (64%) N/A N/A
aSequencing method: variant detected= ‘‘+’’, variant not detected= ‘‘2’’.
b454 depth= total number of non-redundant reads with percentage of variant reads in parentheses.
doi:10.1371/journal.pone.0012295.t002
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a greater number of indels detected by 454, X
2 (2, N=1041) =
146.2, p,0.0001 (Figure 2A). In total, 614 mtDNA variants were
identified by 454 or Sanger sequencing (Table S1). These included
427 (70%) concordant variants (detected by both platforms) and
187 (30%) discordant variants (initially detected by a single
method). The 427 concordant variants consisted of: 412 of 419
(98%) substitutions, 12 of 44 (27%) repeats and 3 of 151 (2%)
indels (Figure 2B). Compared to the concordant variants, the
distribution of 187 discordant variants was significantly different
and included: 7 of 419 (2%) substitutions, 32 of 44 (73%) repeats
and 148 of 151 (98%) indels, X
2 (2, N=614) =526, p, 0.0001
(Figure 2B).
Discordant variants include a potential, novel mtDNA
mutation missed by Sanger
Next, we wanted to determine the possible sources of error for
the seven discordant substitution variants, two (8473T.C and
16566G.A) detected by Sanger and five identified by 454
(Table 2). We first reviewed the Sanger chromatograms and 454
reads that mapped to these positions and concluded that all seven
discordant results were false negative errors. For 8473T.C, the
discordance may be from masking of variant reads by erroneous
454 reads due to the formation of a six base homopolymer (Table
S1). For 16566G.A, we found the variant in all mapped reads at
that position; however, it was not identified as a high confidence
variant.
For the five discordant variants detected by 454 (Table 2),
retrospective review of the initial chromatograms and repeat
Sanger sequencing confirmed the presence of each variant. From
this, we concluded that four false negative errors resulted from
miscalled Sanger sequences, and the fifth Sanger ‘‘miss’’ to the lack
of coverage. We found that the most significant miscall was a
heteroplasmic variant, 7501T.Ci nMT-TS1 for tRNA serine 1
(Figure 3).
Analysis of heteroplasmic mtDNA variants
We next compared the results of 454 and Sanger sequencing for
the detection of heteroplasmic variants defined as having 80% or
less variant read frequency after excluding erroneous reads from a
homopolymer. We evaluated all substitution and indel variants
detected by 454 and excluded repeat polymorphisms because of
the possibility of false positive errors from PCR amplification
[20].
Based on these criteria, we found six heteroplasmic variants of
419 total substitutions. These included four of 412 concordant
substitutions (3243A,G, 9854T,G, 3645T,C and 15222A,G)
with variant read frequencies of 19% to 64% and two of seven
discordant substitutions (16093T.C and 7501T.C) with fre-
quencies of 14% and 18% (Table 2). Similar to 7501T.C, we
failed to identify 16093T.C by our initial Sanger analysis and
detected the variant first by 454 sequencing.
We continued our evaluation to determine the presence of
heteroplasmy for the 151 indels detected by 454 sequencing. Based
on our criteria, indels had a significantly higher proportion of
variants with read frequencies of 80% or less (148 of 151 indels)
compared to substitutions (6 of 419), X
2 (1, N=570) =520,
p,0.0001. However, after reviewing all 454 reads for the 148
indels, we found that each indel was associated with a
homopolymer (4 to 8 bases) at or within four bases of the variant
position (Table S1). So, we concluded that all 148 indels were most
likely homopolymer-associated false positive errors and were not
true heteroplasmic variants, findings consistent with the Sanger
data for these positions.
Performance metrics for 454 and Sanger sequencing
As another means of comparison, we used performance metrics
[11] that we modified to reflect mtDNA genotypes with
heteroplasmy (Table S3). We calculated 454 sequence accuracy
as 99.95% and variant accuracy as 99.5% excluding repeat
polymorphisms. Next, we calculated the error rates and found no
significant difference in the false negative rate for 454 (2 of
421=0.5%) and Sanger (4 of 421=1%), X
2 (1, N=842) =0.168,
p=0.6820. However, we found a significantly greater false positive
rate for 454 (148 of 329938=0.044%) compared to Sanger in
which we did not find false positive errors (0 of 329938=0%), X
2
(1, N=659876) =148.033, p,0.0001, as we expected from
homopolymer-associated 454 indels.
Simulation studies- variant detection at different
coverages
After our comparisons between 454 and Sanger sequencing, we
estimated the minimum 454 sequence coverage for detection of
heteroplasmy (Figure 4 and Table S4). We simulated nine levels of
coverage from 26 to 5006 and then calculated the variant
detection rate for 419 total substitution variants: 6 heteroplasmic
variants and 413 homoplasmic variants. In this analysis, we
excluded repeat polymorphisms and indels because nearly all
Figure 2. Comparison of 454 and Sanger sequencing results. Histograms show the distribution of variants by type: single nucleotide
substitutions (subst), repeats and insertion/deletions (indel). A. Sequencing method. Results are separated by detection using 454 (left panel, light
gray) or Sanger (right panel, dark gray). B. Concordance. Results are separated by concordant detection using 454 and Sanger sequencing (left
panel, dark gray) or by discordant detection, 454 or Sanger sequencing only (right panel, light gray). We observed high concordance between the
two methods for mtDNA substitutions and significant discordance for indels.
doi:10.1371/journal.pone.0012295.g002
Next-Gen MtDNA Sequencing
PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e12295indels were homopolymer-associated false positive errors and the
possibility of the repeats being PCR artifacts. From these
simulations, we estimated that to detect .95% of mtDNA variants
by 454 sequencing, read coverages of at least .206 for
homoplasmy and .2006 for heteroplasmy (range: 10%–80%)
were needed.
Discussion
Roche 454 versus Sanger sequencing for whole mtDNA
analysis
Our results showed that 454 sequencing was comparable to
Sanger sequencing in the detection of single nucleotide substitu-
tions. High concordance (98%) was obtained for the detection of
over 400 single nucleotide substitutions including four hetero-
plasmic variants previously detected by Sanger sequencing. A
previous 454 sequencing study of a 110 kb nDNA region supports
this finding; the study found 98.5% agreement for nearly 400
SNPs at 306average coverage [21].
This high concordance, in addition, is reflected in the high 454
sequencing (99.95%) and variant accuracies (99.5%) in our study.
The 454 sequencing accuracy is consistent with the NGS study
that also directly compared results to Sanger analysis; they
obtained .99.9% 454 sequencing accuracy for a 266 kb nDNA
region in 4 samples with 436average coverage [11]. Our variant
accuracy, however, was significantly greater than the 454 variant
accuracy (93.9%) [11]. Since variant accuracy only includes
Sanger detected variants, one possible explanation for this
difference was our exclusion of repeat polymorphisms—identified
commonly by Sanger but not by 454 sequencing. To confirm these
repeats are real variants (and thus, true 454 false negatives), non-
amplification and single molecule analysis may be possible using
the next wave of sequencing technologies [22].
For our discordant results, not surprisingly, we found 454 indels
consistent with false positive errors from homopolymers in
Figure 4. Coverage simulations and variant detection rate for
mtDNA variants. By subsampling all mapped 454 reads, we simulated
nine levels of coverage (26 to 5006) for 419 mtDNA substitution
variants. Graph shows the variant detection rate by the log10
(coverage) for homoplasmy (black solid line, n=413) and heteroplasmy
(black dashed line, n=6). We estimated that the minimum coverages to
detect 95% of the variants (gray dashed horizontal line) are .206for
homoplasmy and .2006for heteroplasmy.
doi:10.1371/journal.pone.0012295.g004
Figure 3. Novel, potential mtDNA mutation 7501T.C detected by 454 sequencing. A. Case 5 pedigree. Circles represent females and
squares represent males; solid shapes are affected individuals; an arrow indicates the proband that died from sudden cardiac death (SCD). B. 454
sequencing. Shown are representative 454 data flowgrams. We obtained 298 total unique reads, 54 reads had the 7501T.C variant (top) and 244
reads had the reference sequence (bottom). C. Sanger sequencing. Retrospective analysis of Sanger data revealed the missed variant. As shown in
the chromatogram, two peaks are found at position 7501 consistent with a low level of heteroplasmy.
doi:10.1371/journal.pone.0012295.g003
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false negative errors that resulted in an ,0.5% false negative rate.
This rate was less than the 3% 454 false negative rate previously
reported [11], possibly again due our exclusion of repeat
polymorphisms. For SNP calling, previous 454 studies reported
no false negatives with average coverages at 306 [21] and 436
[11].
Including the results of our studies, we concluded that false
negative errors for SNP calling were rare for 454 sequencing. For
one of the 454 false negatives 8473T.C, we concluded it was
from the unusual creation of a new homopolymer with the variant.
The T.C base change created a six cytosine homopolymer
(position 8471–8476) by linking adjacent cytosine bases. The
resulting indel reads (frequency=17%) associated with the
homopolymer may have masked the call of 8473T.C as a high
confidence variant. The second 454 false negative, 16566G.A,
likely resulted from a software error. Although 16566G.A was
found in all mapped sequences (352 unique reads) of the contig,
16566G.A was not called as a 454 variant. In support, we found
the updated Roche GS Mapper software (version 2.3) correctly
called the variant (data not shown).
Taken together, these results show that 454 sequencing was
reliable as Sanger sequencing in the SNP detection. Still, one
concern may be the decreased ability to resolve homopolymeric
regions by 454 sequencing that potentially may mask a mutation at
or adjacent to the region. It is possible that this may have little
impact on the ability to detect mtDNA mutations. We found that
the 148 homopolymer-associated indels involved only 23 nucle-
otide positions (Table S1). The vast majority were located in
coding regions; however, mutations associated with mitochondrial
disease have not been reported at any of these positions (www.
MITOMAP.org).
Detection of missed heteroplasmy by 454 sequencing
With the remaining discordant results, we provide evidence that
454 sequencing may detect variants missed by Sanger analysis—
mtDNA variants with roughly less than 20% heteroplasmy. We
first noted, overall, five Sanger false negatives that resulted in a 1%
Sanger false negative rate. Our estimated rate was less than the 3%
Sanger false negative rate previously reported [11]; we speculate
this difference may be from improved variant detection by
duplicate mtDNA analyses in two laboratories. Still, we had five
Sanger false negatives including two mtDNA variants with low
levels of heteroplasmy (read frequency=14%–18%) and three
homoplasmic variants initially missed by manual inspection or not
identified due to a sequence gap. When we included the four
heteroplasmic concordant variants, our results suggest that 454
sequencing may detect heteroplasmy at the level reliably detected
by Sanger sequencing (above ,20%) [26] but also below that limit
[14].
Of the two heteroplasmic variants missed by Sanger analysis,
7501T.C is a novel, potential mutation in the mtDNA tRNA
serine 1 gene (MT-TS1). Mutations in tRNA serine 1 have been
described in patients with mitochondrial disease [27] but no one
with cardiomyopathy or sudden cardiac death as for our patient
(Case 5). However, although 7501T.C was not found in the
mtDNA databases with more than 5,000 sequences [28,29], it is
possible that 7501T.C is only a benign polymorphism not found
in the specific mtDNA haplogroups comprising the databases. As
another possible explanation, 7501T.C may be one of many
heteroplasmic variants detectable in normal individuals at low
levels [14]. Therefore, we emphasize that we cannot conclude that
7501T.C is truly a mutation until we obtain additional evidence
through family studies, functional studies of 7501T.C for
mitochondrial defects and population studies to investigate the
amount of normal mtDNA variation within this patient’s
haplogroup.
Sequence coverage needed to detect mtDNA variants
In addition to our 454 and Sanger comparisons, we used the
deep 454 sequence coverage (average 13006) and computer
simulations to estimate the minimum amounts of coverage needed
to detect homoplasmic and heteroplasmic mtDNA variants. The
results suggest that 206coverage was needed for homoplasmy and
at least 2006 coverage for heteroplasmy greater than 10%, the
limit of this study. This is consistent with the observed 10-206
coverage sufficient for the detection of homoplasmy in a previous
454 study of 14 mtDNAs [13] and the $2006coverage selected as
criteria for potential heteroplasmy in an Illumina GAII sequencing
study of three mtDNAs [16]. Thus, detection of heteroplasmic
mtDNA variants at frequencies above 10% requires greater 454
coverage than the .306coverage estimated for the detection of
heterozygous nDNA variants [21,30], and detection of hetero-
plasmic variants at lower frequencies may require deeper
sequencing, coverages estimated to be at least 1,5006 for $5%
[15] and 15,0006to 100,0006for as low as 2% [14,31].
In summary, our results support the potential use of 454
sequencing for detection of mtDNA substitutions with hetero-
plasmy of greater than 10%. Using this data, we also estimate a
single 454 GS FLX run would obtain sufficient coverage (206)t o
detect homoplasmic mtDNA variants in 300 mtDNAs. These
results, thus, support high-throughput population studies on
mtDNA variation as another potential use of 454 sequencing
[12,13]. As the performance and output for sequencing technol-
ogies continue to improve, we may anticipate higher accuracies
and deeper coverages that will enable low cost global analysis of
mtDNA variation and highly sensitive mtDNA mutation detec-
tion. We hope that this will identify key genetic determinants for
heart failure, cardiomyopathy and mitochondrial disease leading
to the personalized understanding of disease mechanisms and
personalized treatments.
Materials and Methods
Study population/ethics statement
We evaluated 20 patients referred to Dr. Eloisa Arbustini at
Center for Inherited Cardiovascular Diseases in Pavia, Italy
(Table 1). This included 18 patients with mitochondrial cardio-
myopathy and two suspected of mitochondrial disease. The 20
cases were a subset of 29 cases to be reported on a web-based
bioinformatics approach to identify potential mtDNA mutations
by Sanger sequencing (unpublished data). Case 1 was from
previously reported HCM family with an MYH7 mutation and
possible mtDNA mutation 9957T.C [17]. We obtained informed
written consent of all participants; the study was approved by the
bioethics committee of the IRCCS Foundation Policlinico San
Matteo in Pavia and by the UC Irvine Institutional Review Board
for de-identified DNA samples (#2009-6931).
Mitochondrial DNA sequencing
We extracted genomic DNA from blood except for Case 7 in
which we used heart tissue. Sanger sequencing method (costs
,$130 per mtDNA) and mtDNA data analyses are described in a
separate report (unpublished data).
For Roche 454 sequencing (Figure 5), we first PCR amplified
mtDNA from genomic DNA using Roche Expand Long Range
PCR dNTPack (Roche Applied Science, Indianapolis, IN). Using
three pairs of mtDNA-specific primers, we produced three
Next-Gen MtDNA Sequencing
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7050 bp, position 5061–12111; C: 6866 bp, 11107–1405
(Figure 1). We purified each fragment using Roche High Pure
PCR Product Purification Kit. Primer sequences and PCR
conditions are available upon request.
We conducted Roche 454 FLX sequencing for the 20 cases at
the Genotyping & Sequencing Core/Orphan Disease Testing
Center at the University of California, Los Angeles. Using
standard protocols [23], we ‘‘shotgun’’ sequenced the three
mtDNA PCR fragments for each of the 20 cases (costs ,$835
per mtDNA). First, the three fragments were quantified by
fluorimetry using the PicoGreen Assay, and 2 micrograms of each
fragment were combined. Each of the 20 resulting samples was
sheared using the Covaris system (Covaris, Inc., Woburn, MA)
and the sizes of the DNA fragments were checked using the
Agilent 2100 Bioanalyzer system (Agilent Technologies, Inc.,
Santa Clara, CA). Roche’s 10-base Multiplex Identifier (MID)
Adaptors were added, and equimolar quantities of the tagged
fragments for the first 10 cases and the last 10 cases were pooled
together. For each of the two pooled samples, single-stranded
DNA libraries were made and amplified by emulsion PCR. We
conducted a single 454 sequencing run using one PicoTiterPlate
divided into two regions, each with 10 MID tagged samples.
Bioinformatics analysis
We used the Roche 454 GS Mapper software (version 2.0.01) to
assemble and compare the sequencing reads to the mtDNA
reference sequence [GenBank: NC_012920] [32]. After standard
image and signal processing, we sorted the sequencing reads from
the Standard Flowgram Format (SFF) files using the distinct MID
for each case. Reads were mapped to the reference sequence
which produced a consensus sequence and identified ‘‘high-
confidence differences’’ (HCDiffs). The criteria for HCDiffs were
defined by GS Mapper: variants detected in at least three unique
(non-duplicate) sequencing reads of high quality with both forward
and reverse reads and found in .10% of the total unique
sequencing reads.
We categorized each HCDiff by the variant type (single
nucleotide substitution, insertion/deletion (indel) or repeat poly-
morphism) and by the presence or absence of heteroplasmy.
HCDiffs at positions 303–315, 522–523, 574, 16180–16193 and
16519 were considered repeat polymorphisms [33,34]. For
assessment of heteroplasmy, we developed criteria based on
variant frequency, the number of variant reads divided by the total
number of unique sequencing reads. We also carefully reviewed
the variant and non-variant reads in the HCDiff text files to
identify results most likely due to homopolymers, a known false
positive source because of the technical limitations in 454
pyrosequencing [11,23–25]. We classified an HCDiff as hetero-
plasmic if: (1) the variant frequency was between 0.10 and 0.80
and (2) all non-variant reads contained only the reference allele,
and as homoplasmic if: (1) variant frequency was $0.80 and (2) all
non-variant reads may be explained by a homopolymer error that
occurred at or adjacent to the nucleotide position. Since a variant
had to be detected in .10% of unique reads to be considered an
HCDiff, we did not evaluate variants with #0.10 frequencies.
All new sequence data for the 20 cases has been deposited in
GenBank [accession numbers HM765456-HM765475].
Simulation studies
To estimate the minimal coverage for variant detection, we
calculated the detection rate at different levels of simulated read
coverage. We estimated from an average read length of ,375
bases that 16 coverage of the ,16.5 kb mitochondrial sequence
would be ,50 reads. Therefore, to simulate nine coverage levels
(26,5 6,1 0 6,2 0 6,3 0 6,5 0 6, 1006, 3006 and 5006), we
generated random subsamples of 100, 250, 500, 1000, 1500, 2500,
5000, 15000 and 25000 sequencing reads, respectively for each of
the 20 cases. Three simulations were done for each coverage level.
As before, we used Roche’s GS Mapper to call HCDiffs and then
filtered for single nucleotide polymorphisms. For each coverage
level, we calculated the variant detection rate, the proportion of
HCDiffs called out of the total number variants detected with full
coverage.
Performance metrics and statistical analysis
To compare the mtDNA sequencing performances of the 454
and Sanger platforms, we used defined metrics [11]. We used JMP
7.0 (SAS Institute, Cary, NC) for statistical analysis and graphs.
We considered p,0.05 as a significant difference.
To calculate performance metrics, we defined annotations
that represented genotype differences between 454 and Sanger
Figure 5. Mitochondrial DNA sequencing approach. Schematic
depicts steps in ABI Sanger and Roche 454 sequencing [23]. We isolated
DNA from 20 cases and amplified mitochondrial DNA (mtDNA) by long
range PCR (LR-PCR). We sequenced the PCR fragments using standard
Sanger and 454 sequencing methods. For 454, the fragments were
sheared and then ligated to Multiplex Identifier (MID) adaptors. Next,
we made two pooled samples by combining the tagged fragments for
cases 1–10 and cases 11–20. Single-stranded DNA (ssDNA) libraries were
made from each pooled sample and clonally amplified by emulsion
PCR. Parallel sequencing was done on a single picotiter plate divide into
two regions. The final data, represented as a Sanger chromatogram and
454 flowgrams, are shown.
doi:10.1371/journal.pone.0012295.g005
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mtDNA analysis (Table S3). For this analysis, we excluded the
results for 31 nucleotide positions that had repeat polymorphisms:
303–315, 522–523, 574, 16180–16193 and 16519. When multiple
Sanger sequence peaks are found staggered at these positions, it is
unclear whether this finding resulted from true heteroplasmy or
possibly an artifact due to polymerase error [20,35].
For 454 sequencing, we calculated sequencing and variant
accuracies (Table S3). We defined sequencing accuracy (SA) as the
percentage of the genotype calls that were concordant between
454 and Sanger vs. the sum of numbers of concordant and
discordant calls; it can be also expressed as the symbols defined in
Table S3. SA = (A1 + B2 + C3) / (A1 + A2 + A3 + B1 + B2 + B3
+ C1 + C2 + C3). We defined variant accuracy (VA) as the
percentage of homoplasmic and heteroplasmic variant calls by
Sanger that were concordant with 454 vs. total number of variants
found by both technologies; we calculated variant accuracy as VA
= (B2 + C3) / (A2 + A3 + B2 + B3 + C2 + C3).
Finally, we calculated the false positive and false negative rates
for both platforms (Table S3). The false positive rates were the
proportion of reference genotypes (i.e., confirmed genotypes with
false positive or true negative results) that were called as variants
by each sequencing platform. The false negative rates were the
proportion of variant genotypes (i.e., confirmed genotypes with
false negative or true positive results) that were not called as
variants by each sequencing platform.
Supporting Information
Table S1 Mitochondrial DNA variants identified by 454 and/or
Sanger sequencing, n=614.
Found at: doi:10.1371/journal.pone.0012295.s001 (0.16 MB
XLS)
Table S2 454 Mapping Statistics.
Found at: doi:10.1371/journal.pone.0012295.s002 (0.02 MB
XLS)
Table S3 Sequencing performance metrics: data tables (A) and
calculations (B).
Found at: doi:10.1371/journal.pone.0012295.s003 (0.02 MB
XLS)
Table S4 Coverage simulations for heteroplasmic and homo-
plasmic mtDNA substitutions.
Found at: doi:10.1371/journal.pone.0012295.s004 (0.08 MB
XLS)
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